211 related articles for article (PubMed ID: 34052775)
1. Clinical and immunological characteristics of sarcomas patients with clonogenic tumors.
Avdonkina NA; Danilova AB; Nekhaeva TL; Prosekina EA; Emelyanova NV; Novik AV; Girdyuk DV; Gafton GI; Baldueva IA
Immunobiology; 2021 Jul; 226(4):152094. PubMed ID: 34052775
[TBL] [Abstract][Full Text] [Related]
2. Current status of immunotherapy for sarcomas.
Miwa S; Nishida H; Tsuchiya H
Immunotherapy; 2017 Dec; 9(16):1331-1338. PubMed ID: 29185391
[TBL] [Abstract][Full Text] [Related]
3. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
4. Biological features of tissue and bone sarcomas investigated using an in vitro model of clonal selection.
Avdonkina NA; Danilova AB; Misyurin VA; Prosekina EA; Girdyuk DV; Emelyanova NV; Nekhaeva TL; Gafton GI; Baldueva IA
Pathol Res Pract; 2021 Jan; 217():153214. PubMed ID: 33290900
[TBL] [Abstract][Full Text] [Related]
5. Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis.
Ackermann B; Tröger A; Glouchkova L; Körholz D; Göbel U; Dilloo D
Klin Padiatr; 2004; 216(3):176-82. PubMed ID: 15175963
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients.
Takahashi R; Ishibashi Y; Hiraoka K; Matsueda S; Kawano K; Kawahara A; Kage M; Ohshima K; Yamanaka R; Shichijo S; Shirouzu K; Itoh K; Sasada T
Cancer Sci; 2013 Oct; 104(10):1285-94. PubMed ID: 23829867
[TBL] [Abstract][Full Text] [Related]
7. Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas.
Dancsok AR; Setsu N; Gao D; Blay JY; Thomas D; Maki RG; Nielsen TO; Demicco EG
Mod Pathol; 2019 Dec; 32(12):1772-1785. PubMed ID: 31263176
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral NKp46
Cruz SM; Sholevar CJ; Judge SJ; Darrow MA; Iranpur KR; Farley LE; Lammers M; Razmara AM; Dunai C; Gingrich AA; Persky J; Mori H; Thorpe SW; Monjazeb AM; Murphy WJ; Canter RJ
Front Immunol; 2023; 14():1230534. PubMed ID: 37545516
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5.
Tsukahara T; Kawaguchi S; Torigoe T; Asanuma H; Nakazawa E; Shimozawa K; Nabeta Y; Kimura S; Kaya M; Nagoya S; Wada T; Yamashita T; Sato N
Cancer Sci; 2006 Dec; 97(12):1374-80. PubMed ID: 16995877
[TBL] [Abstract][Full Text] [Related]
10. Immunity against soft-tissue sarcomas.
Maki RG
Curr Oncol Rep; 2003 Jul; 5(4):282-7. PubMed ID: 12781069
[TBL] [Abstract][Full Text] [Related]
11. Bone versus soft-tissue sarcomas in the elderly.
Torigoe T; Terakado A; Suehara Y; Kurosawa H; Yazawa Y; Takagi T
J Orthop Surg (Hong Kong); 2010 Apr; 18(1):58-62. PubMed ID: 20427836
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
Nathenson MJ; Conley AP; Sausville E
Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor.
Montagna D; Turin I; Schiavo R; Montini E; Zaffaroni N; Villa R; Secondino S; Schiavetto I; Caliogna L; Locatelli F; Libri V; Pession A; Tonelli R; Maccario R; Siena S; Pedrazzoli P
Cytotherapy; 2012 Jan; 14(1):80-90. PubMed ID: 21942841
[TBL] [Abstract][Full Text] [Related]
14. Soft tissue sarcoma as a model disease to examine cancer immunotherapy.
Maki RG
Curr Opin Oncol; 2001 Jul; 13(4):270-4. PubMed ID: 11429485
[TBL] [Abstract][Full Text] [Related]
15. [Not Available].
Blay JY
Bull Acad Natl Med; 2015 Jan; 199(1):41-60; discussion 60-1. PubMed ID: 27236877
[No Abstract] [Full Text] [Related]
16. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
17. Transcriptome Analysis of Tumor-Infiltrating Lymphocytes Identifies NK Cell Gene Signatures Associated With Lymphocyte Infiltration and Survival in Soft Tissue Sarcomas.
Judge SJ; Bloomstein JD; Sholevar CJ; Darrow MA; Stoffel KM; Vick LV; Dunai C; Cruz SM; Razmara AM; Monjazeb AM; Rebhun RB; Murphy WJ; Canter RJ
Front Immunol; 2022; 13():893177. PubMed ID: 35874727
[TBL] [Abstract][Full Text] [Related]
18. [Clinical analysis of 51 cases with rare childhood soft tissue sarcomas].
Cai MX; Pan C; Ye QD; Zhou M; Gao YJ; Hu WT; Tang JY
Zhonghua Er Ke Za Zhi; 2016 Dec; 54(12):917-922. PubMed ID: 27938592
[No Abstract] [Full Text] [Related]
19. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
20. High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Children with High-Risk or Recurrent Bone and Soft Tissue Sarcomas.
Choi YB; Yi ES; Lee JW; Yoo KH; Sung KW; Koo HH
J Korean Med Sci; 2016 Jul; 31(7):1055-62. PubMed ID: 27366002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
